Low levels of Vitamin D can lead to hair loss and thinning
The American Diabetes Association (ADA) Standards of Care emphasize individualized therapy selection, with GLP-1 receptor agonists considered preferred agents for many patients with type 2 diabetes who require additional glucose-lowering therapy beyond metformin, particularly those with established cardiovascular disease or chronic kidney disease
and subject to legislative and regulatory changes, ensuring members receive the benefit of prices available through the TrumpRx website as well as counting member payments made on TrumpRx toward deductibles and out-of-pocket maximums
Within this framework, glucagon-like peptide-1 (GLP-1) receptor agonists (RAs), originally developed for the treatment of type 2 diabetes (T2D), have recently shown cardioprotective effects beyond their role in glycaemic control
Fugh-Berman A
Semaglutide works by acting on GLP-1 receptors in the pancreas, gastrointestinal tract, and other areas of the body